Skip to main content
The Application of Clinical Genetics logoLink to The Application of Clinical Genetics
. 2026 Nov 13;19:601102. doi: 10.2147/TACG.S601102

RAD51 and XRCC2 Genetics Variants and Multiple Myeloma Risk, Chromosomal Aberrations, and Clinical Outcomes

Sylwia Popek-Marciniec 1,✉, Wojciech Styk 2, Kinga Sienkiewicz 1, Sylwia Chocholska 3, Aneta Szudy-Szczyrek 3, Marek Hus 3, Joanna Czerwik-Marcinkowska 4, Grażyna Świderska-Kołacz 4, Tadeusz Pietras 5, Szymon Zmorzyński 1
PMCID: PMC13776643  PMID: 43048539

Abstract

Background

Multiple myeloma (MM) is a hematologic malignancy characterized by genomic instability, frequently involving chromosomal translocations and deletions. Such abnormalities often result from DNA double-stranded breaks. RAD51 and XRCC2 gene products play key roles in the homologous recombination repair of these breaks.

Purpose

In this study, we investigated the role of selected genetic variants in MM pathogenesis and progression. Specifically, we analyzed two RAD51 polymorphisms (rs1801321 – 172G>T and rs1801320 – 135G>C) and one in XRCC2 (rs3218536 – Arg188His). The RAD51 variants are located in the 5′ untranslated region and may affect gene regulation or expression, whereas the XRCC2 rs3218536 variant results in an amino acid substitution that may influence protein function. The study aimed to evaluate the associations between these variants and chromosomal aberrations (deletions/translocations), the risk of developing MM, and treatment response.

Patients and Methods

Genomic DNA extracted from 117 newly diagnosed MM patients and 187 healthy blood donors was used to analyze RAD51 and XRCC2 variants (via real-time PCR). The method of cIg-FISH was applied for analysis of chromosomal aberrations. Gene-expression analysis was performed in 85 patient samples from which sufficient high-quality RNA was obtained from isolated CD138-positive plasma cells.

Results

The T allele of RAD51 rs1801321 was associated with a significantly reduced risk of MM (OR = 0.52, 95% CI: 0.37–0.73, p < 0.001). However, RAD51 rs1801320 and XRCC2 rs3218536 showed no association with MM susceptibility. None of the studied variants were found to correlate with chromosomal aberrations or overall survival. Exploratory analyses showed that the rs1801321 T allele and the RAD51 rs1801320 GG genotype were associated with higher XRCC2 expression.

Conclusion

The RAD51 rs1801321 T allele was associated with lower MM susceptibility in the present cohort. However, RAD51 rs1801320 and XRCC2 rs3218536 do not appear to have a significant impact on chromosomal aberrations, disease progression or treatment response.

Keywords: multiple myeloma, DNA repair system, homologous recombination, genetic variants

Introduction

Multiple Myeloma (MM) is the second most common hematologic malignancy.1 The findings of Mousavi et al showed an increasing trend in the incidence of multiple myeloma in both sexes (women and men) between 2000–2019 in the United States of America.2 MM is characterized by clonal expansion of plasma cells in the bone marrow (BM), osteolytic bone disease and monoclonal gammopathy.3 Malignant plasma cells are characterized by genomic instability, including chromosomal aberrations, copy number variants and point mutations.4 The accumulation of these genomic alterations not only drives the progression of the MM disease but also poses challenges for treatment, as they can lead to heterogeneity within the tumor and resistance to therapies. Understanding these genetic changes is crucial for developing targeted therapies and improving patient outcomes.5 According to analyzes conducted by Marfa et al, the estimated incidence and mortality due to MM will increase by 71% and 79% by 2045, respectively, compared to 2022.6 Therefore, it is important to expand knowledge about the risk factors for the development of MM, progression and prediction for effective targeted therapy of this disease.

DNA double-stranded breaks (DSBs) are a severe type of DNA damage in which both strands of the DNA helix are cut at the same or a similar location. These damages are highly dangerous if not repaired and can lead to genome instability (for example deletions, translocations, loss of heterozygosity), point mutations and cell death. In MM, chromosomal translocations and deletions are very common and are key features of genomic instability in this disease.7 They most commonly affect the 14q32 region, ie the locus of the IGH (immunoglobulin heavy chain) gene - t(11;14)(q13;q32), t(4;14)(p16;q32), t(14;16)(q32;q23), t(14;20)(q32;q11). These translocations are not only typical for myeloma, but also have prognostic significance.8,9

Cells use two main pathways for DSB repair: homologous recombination (HR) and non-homologous end joining (NHEJ).10 Homologous recombination is essential for the repair of double-stranded DNA breaks. HR is a multi-stage DNA repair process in which several mediators are involved, primarily BRCA1, BRCA2 and other proteins such as ATM, PALB2, RAD51, MRE11.11,12 The efficiency and activity of HR system directly influence the number of DNA breaks that are repaired, and unrepaired DNA breaks are indeed a significant source of mutations.13 In turn, mutations occurring in somatic cells are the basis for cancer transformation. On the other hand HR pathway mutations can also predict response to anticancer therapies. Mutations that increase the activity of DNA repair systems in cancer cells can lead to drug resistance to cytotoxic drugs. These drugs often work by causing DNA damage, and if cancer cells can effectively repair this damage, they become less susceptible to chemotherapy.

RAD51, as a DNA repair protein, plays a key role in HR. During repair, the RAD51 protein takes part in the homologous pairing process by attaching to the strand. RAD51 forms nucleoprotein fibers and facilitates homology search and attachment.14 There are several known paralogs of the RAD51 protein, including: RAD51B, RAD51C, RAD51D and XRCC2. The role of these proteins in the HR process has been described.14,15 The XRCC2 protein interacts with the RAD51 protein to stabilize it during the HR process.14,15 Moreover, the expression of the RAD51 gene is regulated by the above-mentioned paralogs that are cofactors of this protein.16 Factors regulating the expression of the RAD51 gene also include: transcription factors (CDK, E2F, P53) and genetic variants.16

In our research, we focus on the role of genetic variants in the pathogenesis and course of multiple myeloma and we selected three variants. Two of them concern the RAD51 gene (locus 15q15.1): rs1801321 (172G>T) and rs1801320 (135G>C), and one located in the XRCC2 gene: rs3218536 (Arg188His). Both variants rs1801320 and rs1801321 are located in the 5’untranslated region of the RAD51 gene and may affect gene expression or protein function, potentially affecting the effectiveness of homologous recombination repair.17 The RAD51 gene variants 135 G>C and 172 G>T were checked as a risk factor for various cancers including: head and neck, colorectal, gastric and breast cancer.18–21 Additionally, many studies suggest that variants of the RAD51 gene may contribute to breast carcinogenesis.22,23

XRCC2 gene is located in 7q36.1 and contain an essential part of the homologous recombination repair pathway. This gene is a functional candidate for involvement in cancer progression. Variants in the XRCC2 gene have been reported to be associated with numerous malignancies including: thyroid, breast, ovarian and colorectal cancers.24–27

Bortezomib is a 26S proteasome inhibitor that inhibits the degradation of proteins regulating the cell cycle and apoptosis. It induces ER stress, accumulation of damaged proteins, production of ROS (reactive oxygen species), and DNA damage, including double-strand breaks (DSBs).28,29 Cancer cells with a functional HR pathway (high expression of RAD51/XRCC2) may be better able to repair DNA damage. Bortezomib induces a state of “BRCAness” in MM cells, leading to impaired DNA repair by homologous recombination (HR). This phenomenon involves a reduction in the recruitment of BRCA1 and RAD51 proteins to DNA damage sites, resulting in increased cell sensitivity to PARP inhibitors such as ABT-888.30 In turn, a drug with a different mechanism of action than bortezomib—thalidomide (and its derivatives, such as lenalidomide and pomalidomide)—works by inhibiting cereblon-dependent E3 ligase and has well-documented effects in the treatment of MM. Although their direct effects on RAD51 or XRCC2 have not been clearly established, differences in DNA repair capacity may still contribute to variability in treatment response when these agents are used in combination regimens.31 In recent years, thalidomide has served as a basis for the development of several immunomodulatory imide drugs (IMiDs).32

There is a lot of information about the involvement of the HR repair system in the pathogenesis of breast cancer.33 Most available evidence concerning RAD51 and XRCC2 variants has been obtained from studies of solid tumors.22,23,34 In contrast, substantially less is known about their role in hematological malignancies. The broader discussion of solid-tumor studies is therefore relevant because it provides the principal functional and epidemiological basis for selecting these variants, while simultaneously highlighting the lack of comparable data in MM.

Taking the above into account, we decided to analyze the role of selected genes related to homologous recombination in the development of multiple myeloma. To our knowledge, the correlation of genetic variants of genes related to genetic recombination with the level of DNA damage in multiple myeloma and the risk of developing the disease has not been analyzed.

Materials and Methods

Patients and Samples

The study involved 304 individuals, including 117 newly diagnosed MM patients and 187 healthy blood donors. All participants were from the same ethnic group (Caucasian population). Between 2013 and 2025, biological samples (bone marrow aspirates, peripheral blood, and plasma) were collected from MM patients by clinicians at the Chair and Department of Hematooncology and Bone Marrow Transplantation (Medical University of Lublin, Poland). The characteristics of the MM patients are provided in Table 1. MM bone marrow aspirates were used for cytogenetic analysis and to determine RAD51 and XRCC2 gene expression at the mRNA level. Peripheral blood was used to genotype the RAD51 and XRCC2 genes.

Table 1.

The Characteristics of the MM Patients Included in the Study

Variables MM Patients, n=117
Age (years) 65.7
Sex
Male 64
Female 53
Type of MM*
IgG 63
IgA 28
Light chain 26
Stage according to the International Staging System*
I 12
II 11
III 94
Smoking
Yes 20
No: Nonsmokers 85
No: Ex-smokers 12
Exposure to carcinogenic factors
Yes 26
No 91
Additionally, other type of cancer
Yes 8
No 109
Renal failure*
Yes 25
No 92
The stage of chronic kidney disease (grade)
G1 33
G2 32
G3A 18
G3B 14
G4 10
G5 10
Anemia grade before treatment (WHO)
Absent 28
I – mild 39
II – moderate 38
III – severe 12
Structural cytogenetic changes*
del(17p13.1) 13
del(17p13.1) and t(4;14) 6
del(17p13.1) and t(14;16) 1
t(4;14) 11
t(14;16) 3
Absent 83
Chromosome 17 aneuploidies
Present 38
Absent 79
Chemotherapy
Cyclophosphamide, Thalidomide, and Dexamethasone (CTD) 47
Velcade, Cyclophosphamide, Dexamethasone (VCD), and VD 41
Elcade, Thalidomide, and Dexamethasone (VTD) 26
Died before chemotherapy 19

Note: *at diagnosis.

The control group (for genotyping analysis) consisted of healthy blood donors (51 men and 136 women, with a mean age of 34.8 years) from the Regional Blood Donation and Blood Treatment Center in Kielce, Poland. Nucleated cells were isolated from bone marrow aspirates for gene expression analysis. In this regard, plasma cells were isolated from MM bone marrow aspirates via a magnetic method with CD138+ beads according to the manufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach, Germany).

The study received approvals from the Bioethics Committee at the Medical University of Lublin (Nos. KE-0254/165/2013, KE-0254/337/2016), the Bioethics Committee at Jan Kochanowski University of Kielce (No. KB-41/2016) and the Bioethics Committee at Academy of Zamosc (No. KBAZ/1U/2025), in line with the ethical guidelines set forth by the Helsinki Declaration. All procedures were conducted in compliance with the applicable regulations and standards. Written informed consent was obtained from all participants. The inclusion and exclusion criteria for all study participants are detailed in Table 2.

Table 2.

Inclusion and Exclusion Criteria for MM Patients and Healthy Blood Donors

Inclusion Criteria for MM Patients and Healthy Blood Donors Exclusion Criteria for MM Patients
  • –

    Signed informed consent.

  • –

    18 years of age or older.

  • –

    Successful genotyping.

  • –

    Active smoldering MM.

  • –

    Active plasma cell leukemia.

  • –

    Documented systemic amyloid light chain amyloidosis.

  • –

    Active central nervous system involvement with MM.

Additional inclusion criteria for MM patients Exclusion criteria for healthy donors
  • –

    Newly diagnosed disease.

  • –

    Measurable disease for secretory, poor secretory and non-secretory MM. For secretory MM, the presence of quantifiable monoclonal component, ≥0.5 g/dL, was taken into account. For poor secretory or non-secretory MM, the level of the affected serum free light chain must be ≥10 mg/dL or ≥100 mg/L with an abnormal free light-chain ratio.

  • –

    Eastern Cooperative Oncology Group (ECOG) Performance status ≤3.

  • –

    Life expectancy more than 3 months.

  • –

    HIV infection, hepatitis B or C infection.

  • –

    Bacterial infection resulting in the development of syphilis or tuberculosis.

  • –

    Severe coagulation disorders (eg, hemophilia) or significantly impaired venous access.

  • –

    A condition that requires active medical intervention or monitoring to avert serious danger to the participant’s health or well-being.

DNA Isolation

Genomic DNA was isolated from the peripheral blood of MM patients and healthy blood donors. For this purpose, the Sherlock AX commercial kit (A&A Biotechnology, Gdansk, Poland) was used in accordance with the manufacturer’s recommendations. The concentration and quality of the obtained DNA were then checked using the NanoDrop One device (Thermo Fisher Scientific, Waltham, MA, USA).

DNA Genotyping

We selected the two the most analyzed genetic variants of RAD51 (rs1801321, rs1801320) and one of XRCC2 (rs3218536) genes. Genotyping was performed using TaqMan SNP genotyping assays on CFX Opus 96 Real-Time PCR System (Bio-Rad, California, USA). The results were developed using compatible software CFX Maestro Software (Bio-Rad, California, USA).

cIg-FISH Method

Chromosomal abnormalities with prognostic relevance in multiple myeloma (MM) were assessed using cytoplasmic immunoglobulin and fluorescence in situ hybridization (cIg-FISH), following the guidelines outlined by Ross et al, 2012.35 The culture and staining of malignant plasma cells were performed based on a previously established protocol, with some modifications.36,37 The following probes were used: Vysis TP53/CEP 17 FISH Probe Kit for detection of del(17p13.1), Vysis IGH/FGFR3 DF FISH Probe Kit for detection of t(4;14)(p16;q32), and Vysis IGH/MAF DF FISH Probe Kit for detection of t(14;16)(q32;q23) (Abbott Park, IL, USA). Fluorescent microscopic analysis was performed by scoring 100 AMCA-positive plasma cells to determine the frequency of each aberration. Cut off level were 20% for deletion probes and 10% for dual fusion probes. The interpretation of the results using the specific probes was conducted as described in earlier studies.38

RNA Isolation and Gene Expression Analysis

Total RNA was extracted from the isolated CD138-positive plasma cells using a midi kit (A&A Biotechnology, Gdansk, Poland). The concentration of the isolated RNA was checked using a NanoDrop One spectrophotometer (Thermo Scientific, Waltham, MA, USA). The quality of the nucleic acids was verified by electrophoresis on a 2% agarose gel. The RNA was stored at −80°C. A reverse transcription reaction (RT-PCR) was performed following RNA isolation. RT-PCR mix was performed using a TranScriba noGenome Kit (A&A Biotechnology, Poland) according to the manufacturer’s instructions. cDNA synthesis was performed in T100™ Thermal Cycler (Bio-Rad, California, USA). The qRT-PCR mixture was prepared according to the manufacturer’s protocol (A&A Biotechnology, Gdańsk, Poland). Each reaction mixture was carried out using a 100 ng cDNA template and was performed using SYBR Green RT-PCR Mix (A&A Biotechnology, Poland) and 0.25 µM primers (Genomed, Warsaw, Poland) with an annealing temperature of 60°C. Sequence of primers used: RAD51 forward 5’-GAGGTGAGCTTTCAGCCAGGCAGA-3’ and reverse 5’-TCTGGTTGTTGATGCATGGGCGA-3’; XCCR2 forward 5’-TGTAGTCACCCATCTCTCTGC-3’ and reverse 5’-AGTTGCTGCCATGCCTTACA-3’. Twenty microlitres of the reaction mixture were transferred to each well of the PCR plate. The plate was then centrifuged and placed in a CFX Opus 96 Real-Time PCR System (Bio-Rad, California, USA). All reactions were performed in duplicate. No-template controls were included in each run to exclude contamination (negative control), and melt-curve analysis was performed to confirm the specificity of amplification. Expression was calculated using the 2^(−ΔΔ)Ct method (normalised expression). The expression values are presented as the logarithm to base 2 of R, where R is calculated as follows: R = 2^(−ΔΔCt), where ΔΔCt = ΔCt of the control − ΔCt of the analysed gene and each ΔCt = Ct of the analysed gene − Ct of the endogenous control. The expression of HBB served as a control. For this purpose, 0.25 µM primers (Genomed, Warsaw, Poland) with an annealing temperature of 60°C were used: forward 5’-GAAGAGCCAAGGACAGGTAC-3’; reverse 5’-TGGTCTCCTTAAACCTGTCTTG-3’. A normalized expression (R) in the range of 0.8–1.2 indicated a normal level of gene expression, R < 0.8 indicated low expression, and R > 1.2 indicated high expression.39,40

Statistical Analysis

The laboratory results of MM patients were compared to those of patients with the studied genotypes using t-tests (for continuous variables) and chi-square tests (for categorical variables). Associations between genotypes and clinical data were evaluated using the chi-square test or Fisher’s exact test (for categories with an expected value <5). Quantitative data are presented as frequencies or percentages. Hardy–Weinberg equilibrium (HWE) was tested with the chi-square test, applying Yates correction for groups with fewer than five individuals. For the 95% confidence intervals (CIs), a threshold of p = 0.05 and χ2 = 3.84 was used; thus, if χ2 ≤ 3.84 and p ≥ 0.05, the population was considered to be in HWE. Univariate and multivariate analyses of overall survival (OS) and progression-free survival (PFS) were conducted using the Cox proportional hazard model. Survival analysis was performed using the Kaplan–Meier method and the Log rank test. The statistical power of the study was calculated according to Bacchetti and Leung.41

A significance level of p < 0.05 was used, indicating statistically significant differences. Statistical analyses were carried out using Statistica ver. 12.5 (StatSoft, Krakow, Poland).

Results

The present study included 117 MM patients. The rs1801320 and rs1801321 variants of RAD51 gene, as well as rs3218536 variant of the XRCC2 gene were analyzed.

Analysis of Allele and Genotype Frequencies in Relation to Multiple Myeloma Susceptibility

Genotyping was successfully performed for all participants included in the study, fulfilling a key inclusion criterion for both multiple myeloma patients and healthy blood donors. The populations of MM patients and healthy blood donors were in HWE (Table 3). The presence of T allele of rs1801321 in all types of models decreased the risk of MM development (Table 4). We did not observe statistically significant differences between genotype and allele frequencies among MM patients and healthy blood donors in the case of rs1801320 and rs3218536 variants (Table 4).

Table 3.

Hardy-Weinberg Equilibrium (HWE) for RAD51 and XRCC2 Variants in the Case and Control Groups According to Expected (E) and Observed (O) Values

Groups Genotypes Total HWE
p value and χ2*
rs1801320 (of RAD51)
– GG GC CC – –
CONTROL
E 133.5 49 4.5 187 p=0.05
χ2=3.82
O 137 42 8 187
CASE
E 92.4 23.1 1.4 117 p=0.17
χ2=1.82
O 91 26 0 117
rs1801321 (of RAD51)
GG GT TT – –
CONTROL
E 83.6 82.9 20.6 187 p=0.14
χ2=2.15
O 88 74 25 187
CASE
E 28.3 63.3 35.3 117 p=0.55
χ2=0.34

Table 4.

Comparison of Allele Frequencies and Distribution of RAD51 and XRCC2 Variants Between MM Patients and Healthy Controls

Gene Variants and Alleles MM
n (%)
Controls
n (%)
Odds Ratio 95% CI p values
rs1801320
DOMINANT
GG 91 (77.8%) 137 (73.3%) 1 – –
GC 26 (22.2%) 42 (22.4%) 1.07 0.61–1.87 0.80
CC 0 (0%) 8 (4.3%) * * *
GC+CC 26 (22.2%) 50 (26.7%) 1.26 0.74–2.19 0.37
RECESSIVE
GG+GC 117 (100%) 179 (95.7%) 1 – –
CC 0 (0%) 8 (4.3%) * * *
OVER DOMINANT
GG+CC 91 (77.8%) 145 (77.6%) 1 – –
GC 26 (22.2%) 42 (22.4%) 1.01 0.58–1.76 1.0
Total: 117 (100%) 187 (100%)
ALLELES
G 208 (88.9%) 316 (84.5%) 1 – –
C 26 (11.1%) 58 (15.5%) 1.46 0.89–2.40 0.12
Total: 234 (100%) 374 (100%)
rs1801321
DOMINANT
GG 30 (25.6%) 88 (47%) 1 – –
GT 60 (51.3%) 74 (39.6%) 0.42 0.24–0.72 0.001
TT 27 (23%) 25 (13.4%) 0.31 0.16–0.62 <0.001
GT+TT 87 (74.3%) 99 (53%) 0.39 0.23–0.64 <0.001
RECESSIVE
GG+GT 90 (77%) 162 (86.6%) 1 – –
TT 27 (23%) 25 (13.4%) 0.51 0.28–0.94 0.028
OVER DOMINANT
GG+TT 57 (48.7%) 113 (60.4%) 1 – –
GT 60 (51.3%) 74 (39.6%) 0.62 0.39–0.99 0.045
Total: 117 (100%) 187 (100%)
ALLELES
G 120 (51.3%) 250 (66.8%) 1 – –
T 114 (48.7%) 124 (33.2%) 0.52 0.37–0.73 <0.001
Total: 234 (100%) 374 (100%)
rs3218536
DOMINANT
CC 96 (82%) 148 (79.1%) 1 – –
CT 19 (16.2%) 34 (18.2%) 1.16 0.62–2.15 0.64
TT 2 (1.7%) 5 (2.7%) 1.62 0.31–8.53 0.85
CT+TT 21 (18%) 39 (33.3%) 1.20 0.67–2.17 0.53
RECESSIVE
CC+CT 115 (98.3%) 182 (97.3%) 1 – –
TT 2 (1.7%) 5 (2.7%) 1.58 0.30–8.28 0.88
OVER DOMINANT
CC+TT 98 (83.7%) 153 (81.8%) 1 – –
CT 19 (16.2%) 34 (18.2%) 1.14 0.62–2.12 0.66
Total: 117 (100%) 187 (100%)
ALLELES
C 211 (90.2%) 330 (88.2%) 1 – –
T 23 (9.8%) 44 (11.8%) 1.22 0.72–2.08 0.46
Total: 234 (100%) 374 (100%)

Note: * too small group for analysis.

Chromosomal Aberrations and Studied Variants

The number of individuals exhibiting deletions of 17p13.1 and chromosome 17 aneuploidies was relatively low, with 20 and 38 cases, respectively. Notably, 17p13.1 deletions were observed to co-occur with chromosome 17 aneuploidies. Within this group, we identified trisomy 17 (n = 16), tetrasomy 17 (n = 3), and monosomy 17 (n = 1). Given the limited number of each specific aberration, these chromosomal alterations were combined into a single group for further analysis. We did not observe an association between the studied variants and the presence of chromosome 17 aneuploidies—rs1801320, p=0.62 (OR=1.68, 95% CI 0.45–6.28); rs1801321, p=0.30 (OR=1.71, 95% CI 0.61–4.79); and rs3218536, p=0.97 (OR=1.22, 95% CI 0.32–4.63). Due to the limited number of patients with structural cytogenetic abnormalities, individuals with del(17)(p13.1) involving the TP53 gene locus and those with translocations at 14q32.2 affecting the IgH gene locus were grouped together for analysis. We did not observe an association between cytogenetic structural aberrations and the studied genetic variants – rs1801320 (p=0.057, OR=3.79, 95% CI 1.05–13.65); rs1801321 (p=0.71, OR=2.13, 95% CI 0.33–2.13); rs3218536 (p=0.84, OR=1.30, 95% CI 0.43–3.91). Additionally, we did not observe any differences in the expression of the genes studied in relation to chromosomal aberrations.

Association of RAD51 and XRCC2 Polymorphisms with Mortality and Progression Risk in MM

Due to the small number of individuals carrying minor genotypes, these were combined with heterozygotes for the purposes of statistical analysis. Univariate Cox regression analysis demonstrated that patients who underwent autologous hematopoietic stem cell transplantation (autoHSCT) showed a significantly reduced risk of death (HR = 0.27; p<0.001) (Table 5). Similar findings were observed for disease relapse or progression in MM patients with autoHSCT (Table 5). The statistical power of this association was 0.63. Cox regression analyses (univariate and multivariate) revealed no significant impact of the analyzed genotypes on MM outcomes, including mortality, relapse, or progression.

Table 5.

Univariate Cox Analysis in Survival of MM Patients

Variable Univariate Cox Analysis for OS Univariate Cox Analysis for PFS
p value HR 95% CI p value HR 95% CI
Auto-HSCT
Yes <0.001 0.27 0.11–0.76 0.04 0.44 0.21–0.98
No – R – – R –
rs1801320
GG – R – – R –
GC+CC 0.82 0.89 0.34–2.32 0.06 0.41 0.16–1.05
rs1801321
GG – R – – R –
GT+TT 1.0 0.99 0.40–2.44 0.64 1.22 0.53–2.81
rs3218536
CC – R – – R –
CT+TT 1.0 1.01 0.35–2.88 0.36 0.64 0.24–1.69

Associations of the Studied Variants with Clinical/Laboratory Values

The potential associations between clinical and laboratory parameters and selected genotypes of the RAD51 and XRCC2 genes were investigated. We observed statistically significantly shorter time to auto-HSCT in patients with GG genotype of rs1801321 variant (Table 6). Depending on the RAD51 gene variants, we observed statistically significant changes in the expression of the XRCC2 gene. The GG rs1801320 genotype was found to be associated with statistically significantly higher expression of the XRCC2 gene than the GC+CC genotypes of RAD51 gene (Table 6). The presence of the T allele of the rs1801321 RAD51 variant was found to be associated with significantly higher XRCC2 gene expression. In the case of other variables comparative analysis revealed no statistically significant differences in clinical or laboratory findings among patients carrying different variants of the rs1801320, rs1801321 and rs3218536 polymorphisms (Table 6). The lack of statistically significant associations with cytogenetic and clinical outcomes should be interpreted cautiously because some subgroup analyses may have been underpowered.

Table 6.

Clinical Data of MM Patients in Relation to Studied Genotypes

Variables MM Patients rs1801320 rs1801321 rs3218536
GG GC+CC p-value GG GT TT p-value CC CT+TT p-value
Mean age (years) 65.7±9.54 65.57±9.63 65.96±9.62 0.83 67.70±9.84 64.03±9.40 67.04±9.40 0.16 65.01±9.54 68.75±9.42 0.11
Free light chain ratio 264.72±723.21 292.32±809.29 164.29±48.40 0.47 111.96±742.31 204.15±723.21 580.76±725.94 0.73 269.75±783.29 240.59±353.34 0.56
% of plasma cells in bone marrow 33.75±18.30 33.23±18.30 35.68±18.94 0.62 30.93±19.05 36.38±19.51 30.96±14.16 0.28 33.60±18.41 34.50±18.68 0.79
Albumins (g/dL) 3.62±0.66 3.69±0.66 3.41±0.68 0.08 3.63±0.77 3.59±0.66 3.70±0.58 0.78 3.60±0.68 3.77±0.58 0.40
β2-microglobulin (mg/L) 6.83±5.90 6.77±6.25 7.06±4.71 0.56 6.66±4.57 7.05±7.16 6.53±4.04 0.92 6.87±6.14 6.66±4.94 0.94
Calcium (mM/L) 2.47±0.35 2.45±0.31 2.56±0.49 0.59 2.50±0.39 2.47±0.37 2.45±0.30 0.82 2.46±0.34 2.52±0.46 0.83
Hemoglobin (g/dL) 10.31±1.79 10.38±1.75 10.08±2.0 0.33 10.23±1.61 10.20±1.83 10.69±1.94 0.48 10.34±1.83 10.19±1.70 0.71
Creatinine (mg/dL) 1.65±1.65 1.56±1.63 1.63±1.69 0.26 1.55±1.30 1.72±1.96 1.49±1.17 0.80 1.66±1.72 1.46±1.23 0.56
Platelets (K/μL) 212.06±91.59 213.45±78.46 207.04±132 0.24 212.43±77.48 213.58±107.43 208.15±68.56 0.97 215.65±94.90 194.90±76.23 0.67
C-reactive protein (mg/L) 15.39±31.79 13.89±32.36 20.89±30.30 0.17 20.14±32.79 16.73±31.79 6.83±31.91 0.53 15.77±32.84 13.60±27.85 0.59
Estimated glomerular filtration rate mL/min/1.73m2 67.05±32.53 67.26±31.21 66.32±38.24 0.99 65.23±32.50 69.07±32.39 64.53±34.51 0.79 66.36±32.92 70.42±32.09 0.54
Number of chemotherapy cycles 5.82±2.34 6.04±2.28 5.04±2.52 0.07 5.43±2.45 6.28±2.20 2.23±2.47 0.09 5.95±2.38 5.25±2.20 0.17
Time to auto-HSCT (months) 3.20±6.16 3.34±6.53 2.72±4.84 0.93 1.0±6.18 4.21±6.16 3.42±6.18 0.03 3.31±6.50 2.70±4.51 0.96
RAD51 expression 3.12±1.68 3.16 ±1.67 2.77±1.54 0.36 3.26±1.56 2.78±1.65 3.37 ±3.29 0.32 2.94 ±1.53 3.86 ±2.10 0.07
XRCC2 expression 5.87 ±2.40 6.19 ±2.32 4.85±2.51 0.03 4.63*** ±2.48 6.04* ±2.43 6.45**±4.85 0.045 5.85 ±2.50 6.03 ±1.95 0.81

Notes: * p value GG vs GT = 0.043. **p value GG vs TT = 0.01.

Survival of MM Patients

The analyzed haplotypes of RAD51 gene did not affect OS in MM patients (Table 7). Furthermore, the associations between the analyzed genotypes and OS in MM patients were evaluated using the Log rank test. The studied variants did not affect OS (log rank test for rs1801320 p=0.90; rs1801321 p=0.36, rs3218536 p=0.66) or PFS (log rank test for rs1801320 p=0.50; rs1801321 p=0.50, rs3218536 p=0.89) without considering the type of treatment.

Table 7.

Haplotypes Comprising RAD51 Gene Variants and OS

rs1801320 1801321 Frequency OS (Months) Standard Deviation p value
GG GG 0.16 18.52 15.52 0.19
GC GT 0.10 27.58 22.55

Discussion

Genomic instability, particularly in the form of chromosomal translocations and deletions, is a hallmark of MM and plays a critical role in disease development and progression.42 DNA double-strand breaks are key events driving such instability, and their accurate repair is essential for maintaining genomic integrity.43 Among the key proteins involved in homologous recombination repair are those encoded by the RAD51 and XRCC2 genes.44 Variants within these genes may impair DNA repair efficiency, potentially contributing to the accumulation of cytogenetic abnormalities and influencing disease course or response to therapy. In this study, we explored the association of selected RAD51 (rs1801321 and rs1801320) and XRCC2 (rs3218536) polymorphisms with chromosomal aberrations, MM susceptibility, and treatment response. While our findings did not confirm a significant relationship between these variants and chromosomal abnormalities or MM risk, one association was noted with treatment timing, warranting further investigation.

In the our study, the T allele of the RAD51 rs1801321 variant was significantly associated with a lower risk of multiple myeloma. In contrast, no significant association with multiple myeloma susceptibility was observed for RAD51 rs1801320 or XRCC2 rs3218536. These findings suggest that the investigated variants may differ in their relevance to disease susceptibility. However, the association observed for rs1801321 should be interpreted cautiously and requires confirmation in an independent cohort.

RAD51 recombinase and its paralog XRCC2 protein are the elements of the protein complex performing DNA DSBs repair by HR. Genetic variation in DNA double-strand break repair genes such as RAD51 gene and XRCC2 may contribute to the occurrence and progression of MM. RAD51 polymorphism rs1801321 is one of the most common polymorphisms located at the 5’UTR.17 To date, RAD51 gene variants have not been studied in MM. Sassi et al described the association between the rs1801321 variant of RAD51 gene and lymph node metastasis in breast cancer patients.22

A comprehensive meta-analysis conducted by Khan et al provided solid evidence that the RAD51 rs1801320 CC genotype significantly increases the risk of developing breast cancer.23 Khan et al performed a meta-analysis that aimed to assess the relationship between RAD51 rs1801320 polymorphism and breast cancer susceptibility.23 Their comprehensive meta-analysis of 16 case-control studies, including 4743 cases and 4448 controls, showed a definite association between the RAD51 rs1801320 polymorphism and breast cancer risk. These findings revealed a strong association with the CC genotype, demonstrating its significant role in breast cancer susceptibility.23 The referenced meta-analysis was conducted in response to inconsistent findings regarding the association between the rs1801320 variant and breast cancer risk. While several studies reported no statistically significant differences in genotype or allele frequencies between breast cancer patients and control groups,45,46 others demonstrated a positive correlation between the variant and disease susceptibility.47,48 Additionally, some findings suggested a potential protective effect of this polymorphism.49,50 Moreover, the association of C allele of rs1801320 variant with an increased risk of head and neck cancer has been described.21 Results published by Mohseni et al, showed that carriers of the RAD51 rs1801320 C allele variant (GC + CC) were associated with resistance to induction therapy (OR: 4.7, p = 0.012).51 The research was conducted among patients with acute myeloid leukemia (AML). Additionally, these studies showed that patients with the C allele (GC + CC) were protected from liver toxicity compared to those with wild-type (GG) alleles (OR: 0.315, p = 0.031).51 RAD51 is a poor prognostic marker for oral squamous cell carcinoma. High RAD51 protein expression associates with resistance to chemotherapy and radiotherapy.16 A study examining the RAD51 gene rs1801320 (135G/C polymorphism) and its association with colorectal cancer risk in the Polish population found no significant association.52 The study by Poplawski et al, examined the relationship between DNA damage, its repair mechanisms, and the development of gastric cancer, focusing on the effects of hOGG1 and RAD51 gene variants. Their result suggested that the G135C polymorphism of the RAD51 gene may be linked with gastric cancer by the modulation of the cellular response to oxidative stress.18 A meta-analysis by Wang et al suggests that the homozygote of the 135 C variant of the RAD51 gene is associated with an increased risk of breast cancer in carriers of the BRCA2 gene mutation. Moreover, in their meta-analysis, highly heterogeneity was observed in acute myeloid leukemia, especially in Caucasians.24 Most studies on the rs1801320 variant have been conducted on solid tumors. Few studies of this polymorphism have been conducted on hematopoietic cancers. An example of the analysis of the rs1801320 variant in leukemias is the above-mentioned study conducted by Mosheni et al.51 In turn, Rollinson et al demonstrated that the protective effect associated with the C allele of rs1801320 was linked to the inheritance of the RAD51 135 (rs1801320) – 172 (rs1801321) C-G haplotype.53 In our study, these haplotypes did not show a protective effect in patients with MM. Seedhouse et al demonstrated that double-strand DNA breaks and their repair play an important role in the pathogenesis of both de novo and therapy-related-AML.54 Voso et al, found a significantly higher incidence of polymorphic variants of the RAD51 gene (rs1801320) in AML cases compared to controls.55 They described that carriers of the variant C allele at position −135 in the RAD51 gene were more common among AML patients compared to controls (p = 0.024). This resulted in a 2.09-fold increase in AML risk in rs1801320 variant carriers of the C allele.55 However, a meta-analysis conducted by Li et al did not confirm a link between RAD51 and XRCC2 gene variants and the risk of developing AML.56

The non-synonymous variant rs3218536, arising from a c.563G>A substitution in exon 3 of the XRCC2 gene, leads to an amino acid change from arginine to histidine at codon 188.57 Although direct studies of the rs3218536 polymorphism in leukemia are limited, there is evidence that changes in XRCC2 gene expression may influence the development and progression of leukemia.58 It is worth noting that the rs3218536 polymorphism is non-synonymous and may affect the function of the XRCC2 protein, which could potentially be significant in the context of hematological malignancies. This polymorphism has been suggested to be linked with an elevated risk of breast cancer.59 The XRCC2 gene encodes one of the key proteins involved in the repair of double-strand DNA breaks through homologous recombination, a mechanism that is particularly important in cells with high proliferative activity, such as cancer cells.44 The rs3218536 (Arg188His) can lead to a change in the structure of the XRCC2 protein, which potentially affects the efficiency of DNA repair and may promote genomic instability, a characteristic feature of multiple myeloma.57 Reduced DNA repair efficiency may contribute to the accumulation of mutations, the development of chromosomal aberrations, and disease progression. Although this variant has been studied in the context of various cancers, such as breast,57 ovarian,25 and head and neck cancer,60 its role in multiple myeloma remains unclear. Moreover, a meta-analysis study by Wang et al suggests that the XRCC2 Arg188His polymorphism may be a risk factor for CRC.61 In our studies, we did not observe any association between the rs3218536 variant and the occurrence of chromosomal aberrations, the risk of developing MM, or the response to treatment for this disease. It is possible that repair mechanisms in breast cancer make more intensive use of processes involving the XRCC2 protein. However, to our knowledge, this is the first study of its kind conducted in MM.

Our study found that the rs1801320 and rs1801321 variants of the RAD51 gene significantly affected XRCC2 gene expression. The RAD51 and XRCC2 genes operate in the same DNA repair pathway. Changes in one element of this pathway can lead to the compensatory regulation of other genes within it. A trans-regulatory effect occurs when variants in one gene affect the expression of another gene.62 The observed relationship between RAD51 polymorphisms and XRCC2 expression suggests the existence of trans-regulatory mechanisms that control homologous recombination repair gene expression. These mechanisms are potentially important in the biology of multiple myeloma. Although trans-regulatory mechanisms are well documented, there is currently no evidence to suggest that they occur between the RAD51 and XRCC2 genes. DNA variants that alter gene expression are responsible for the variability of many phenotypic traits. Trans-acting variants, which are frequently found on chromosomes different to those of the genes they affect, are a significant source of heritable variation in gene expression.63

Bortezomib, a drug used to treat cancers, including multiple myeloma, disrupts the DNA repair pathway dependent on FANC proteins (ie, the Fanconi pathway). When cells are treated with bortezomib the activity of two important DNA repair mechanisms decreases significantly - HR and alternative DNA end joining.64 The study by Jacquemont et al showed that inhibition of proteasome activity with bortezomib, as well as reduction of 19S and 20S proteasome subunits, weakens DNA damage signaling, including RAD51.65 In our study, we hypothesised that variants of the RAD51 gene may be associated with the response to bortezomib treatment. However, this hypothesis was not confirmed by our study.

The present findings should be regarded as preliminary and hypothesis-generating. The observed associations require confirmation in larger, independent cohorts and functional studies before firm biological conclusions can be drawn.

A key limitation of our study is the relatively small sample size, which may have influenced the statistical power of our analyses. This constraint is partly attributable to the low incidence of MM. Future studies involving larger patient cohorts are warranted to more comprehensively assess the role of RAD51 and XRCC2 gene variants in MM pathogenesis. Additionally, we did not investigate RAD51 and XRCC2 expression at either the mRNA or protein level, nor did we analyze gene expression dynamics during disease progression or following treatment. Such analyses could provide valuable insights into how the expression of these genes changes in response to therapeutic interventions and at different disease stages. Furthermore, our study did not include patients with relapsed or refractory MM. Including this subgroup in future research may help clarify the potential impact of the studied variants on disease behavior and treatment response in advanced or resistant forms of MM.

Our findings did not confirm a significant association between the analyzed RAD51 and XRCC2 gene variants and key clinical and biological features of MM. Specifically, no associations were observed between these polymorphisms and the presence of chromosomal aberrations commonly seen in MM patients. Although the analyzed genes play essential roles in DNA repair pathways, our results suggest that the selected polymorphisms may not have a substantial impact on MM development or clinical outcomes in the studied cohort. Further studies in larger and more diverse populations are needed to fully evaluate their potential role.

Conclusion

The following conclusions can be drawn based on the research conducted: (I) rs1801321 (RAD51) may be associated with susceptibility to MM. The observed association of the T allele with a lower risk of MM may indicate a potential protective effect, although the underlying biological mechanism requires functional validation; (II) no statistically significant associations were observed between rs1801320 (RAD51) and rs3218536 (XRCC2) and the risk of developing MM in the studied cohort; (III) the studied variants were not significantly associated with major cytogenetic markers of poor prognosis in multiple myeloma (MM). While these findings do not support an association with these cytogenetic abnormalities, larger studies are needed to confirm this observation; (IV) the analysed RAD51 and XRCC2 polymorphisms were not associated with clinical outcomes in this cohort, meaning they did not demonstrate prognostic value in the present study; (V) an association between RAD51 polymorphisms and XRCC2 expression was observed. However, the biological significance of this relationship remains to be elucidated in functional studies. Due to the lack of correction for multiple comparisons and the observational nature of the study, these findings should be treated as exploratory and require validation through larger, independent cohorts and functional investigations.

Funding Statement

This project was supported by Ministry of Higher Education and Science, Poland - grant number NdS-II/SP/0066/2024/01 (SZ, SP-M and WS); and grant number SUPB.RN.21.234 (J.C-M.).

Institutional Review Board Statement

The study obtained positive opinions from the Bioethics Committee at the Medical University of Lublin (Nos. KE-0254/165/2013, KE-0254/337/2016), the Bioethics Committee at Jan Kochanowski University of Kielce (No. KB-41/2016) and the Bioethics Committee at Academy of Zamosc (No. KBAZ/1U/2025), according with the ethical standards established by Helsinki Declaration. All methods were performed in accordance with the relevant guidelines and regulations. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Abbreviations

AML, Acute myeloid leukemia; BM, Bone marrow; CRC, Colorectal cancer; DSBs, DNA double-stranded breaks; HR, Homologous recombination; HWE, Hardy-Weinberg equilibrium; MM, Multiple Myeloma; NHEJ, Non-homologous end joining; OS, Overall Survival; PFS, Progression-free survival; 5’UTR, 5’ untranslated region.

Data Sharing Statement

The clinical data used to support the findings of this study are available from the corresponding author upon request.

Informed Consent Statement

Written informed consent has been obtained from all subjects involved in the study.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in conception, study design, execution, acquisition of date, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects if the work.

Disclosure

The authors declare no conflicts of interest.

References

  • 1.Kundu S, Jha SB, Rivera AP, et al. Multiple myeloma and renal failure: mechanisms, diagnosis, and management. Cureus. 2022. doi: 10.7759/cureus.22585 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mousavi SE, Ilaghi M, Aslani A, Yekta Z, Nejadghaderi SA. A population-based study on incidence trends of myeloma in the United States over 2000–2020. Sci Rep. 2023;13(1):20705. doi: 10.1038/s41598-023-47906-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma. Jama. 2022;327(5):464. doi: 10.1001/jama.2022.0003 [DOI] [PubMed] [Google Scholar]
  • 4.Ram M, Fraser M, Vieira Dos Santos J, et al. The genetic and molecular drivers of multiple myeloma: current insights, clinical implications, and the path forward. Pharmgenomics Pers Med. 2024;17:573–17. doi: 10.2147/PGPM.S350238 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Jurczyszyn A, Charliński G, Suska A, Vesole DH. The importance of cytogenetic and molecular aberrations in multiple myeloma. Acta Haematol Pol. 2021;52(4):361–370. doi: 10.5603/AHP.2021.0069 [DOI] [Google Scholar]
  • 6.Mafra A, Laversanne M, Marcos-Gragera R, et al. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. JNCI J Nat Cancer Inst. 2025;117(5):907–914. doi: 10.1093/jnci/djae321 [DOI] [PubMed] [Google Scholar]
  • 7.Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024;64:101168. doi: 10.1016/j.blre.2024.101168 [DOI] [PubMed] [Google Scholar]
  • 8.Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol. 2005;23(26):6339–6344. doi: 10.1200/JCO.2005.05.023 [DOI] [PubMed] [Google Scholar]
  • 9.Lakshman A, Alhaj Moustafa M, Rajkumar SV, et al. Natural history of t(11;14) multiple myeloma. Leukemia. 2018;32(1):131–138. doi: 10.1038/leu.2017.204 [DOI] [PubMed] [Google Scholar]
  • 10.Tan J, Sun X, Zhao H, Guan H, Gao S, Zhou P. Double-strand DNA break repair: molecular mechanisms and therapeutic targets. MedComm. 2023;4(5):e388. doi: 10.1002/mco2.388 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination–related gene mutations across multiple cancer types. JCO Precis Oncol. 2018;(2):1–13. doi: 10.1200/PO.17.00286 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Toh M, Ngeow J. Homologous recombination deficiency: cancer predispositions and treatment implications. Oncologist. 2021;26(9):e1526–e1537. doi: 10.1002/onco.13829 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Rodgers K, McVey M. Error-prone repair of DNA double-strand breaks. J Cell Physiol. 2016;231(1):15–24. doi: 10.1002/jcp.25053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Greenhough LA, Liang CC, Belan O, et al. Structure and function of the RAD51B–RAD51C–RAD51D–XRCC2 tumour suppressor. Nature. 2023;619(7970):650–657. doi: 10.1038/s41586-023-06179-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Masson JY, Tarsounas MC, Stasiak AZ, et al. Identification and purification of two distinct complexes containing the five RAD51 paralogs. Genes Dev. 2001;15(24):3296–3307. doi: 10.1101/gad.947001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tsai YF, Chan LP, Chen YK, et al. RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma. Cancer Cell Int. 2023;23(1):231. doi: 10.1186/s12935-023-03071-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Alomair A, Alamri A, Shaik J, Aljafari S, Ba Abdullah M, Alanazi M. Association between polymorphisms of the DNA repair genes RAD51 and OGG1 and risk of cardiovascular disease. Mol Med Rep. 2024;29(3):53. doi: 10.3892/mmr.2024.13177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Poplawski T, Arabski M, Kozirowska D, et al. DNA damage and repair in gastric cancer—A correlation with the hOGG1 and RAD51 genes polymorphisms. Mutat Res. 2006;601(1–2):83–91. doi: 10.1016/j.mrfmmm.2006.06.002 [DOI] [PubMed] [Google Scholar]
  • 19.Cheng D, Shi H, Zhang K, Yi L, Zhen G. RAD 51 Gene 135G/C polymorphism and the risk of four types of common cancers: a meta-analysis. Diagn Pathol. 2014;9(1):18. doi: 10.1186/1746-1596-9-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Krupa R, Sliwinski T, Wisniewska-Jarosinska M, et al. Polymorphisms in RAD51, XRCC2 and XRCC3 genes of the homologous recombination repair in colorectal cancer—a case control study. Mol Biol Rep. 2011;38(4):2849–2854. doi: 10.1007/s11033-010-0430-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Sliwinski T, Walczak A, Przybylowska K, et al. Polymorphisms of the XRCC3 C722T and the RAD51 G135C genes and the risk of head and neck cancer in a Polish population. Exp Mol Pathol. 2010;89(3):358–366. doi: 10.1016/j.yexmp.2010.08.005 [DOI] [PubMed] [Google Scholar]
  • 22.Sassi A, Popielarski M, Synowiec E, Morawiec Z, Wozniak K. BLM and RAD51 genes polymorphism and susceptibility to breast cancer. Pathol Oncol Res. 2013;19(3):451–459. doi: 10.1007/s12253-013-9602-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Khan NU, Alqarni SS, Yousuf A, et al. The influence of RAD51 (rs1801320) on breast cancer risk: an updated meta-analysis. Discover Oncol. 2025;16(1):289. doi: 10.1007/s12672-025-02012-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wang W, Li JL, He XF, et al. Association between the RAD51 135 G>C polymorphism and risk of cancer: a meta-analysis of 19,068 cases and 22,630 controls. PLoS One. 2013;8(9):e75153. doi: 10.1371/journal.pone.0075153 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Yuan C, Liu X, Li R, Yan S, Kong B. Analysis of the association between the XRCC2 rs3218536 polymorphism and ovarian cancer risk. Arch Med Sci. 2020;16(3):682–691. doi: 10.5114/aoms.2020.94657 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Lin WY, Camp NJ, Cannon-Albright LA, et al. A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J Med Genet. 2011;48(7):477–484. doi: 10.1136/jmedgenet-2011-100018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Yan L, Li Q, Li X, Ji H, Zhang L. Association studies between XRCC1, XRCC2, XRCC3 polymorphisms and differentiated thyroid carcinoma. Cell Physiol Biochem. 2016;38(3):1075–1084. doi: 10.1159/000443058 [DOI] [PubMed] [Google Scholar]
  • 28.Briest F, Koziolek EJ, Albrecht J, et al. Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? – a preclinical assessment in vitro and in vivo. Neoplasia. 2021;23(1):80–98. doi: 10.1016/j.neo.2020.11.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Selimovic D, Porzig BBOW, El-Khattouti A, et al. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells. Cell Signal. 2013;25(1):308–318. doi: 10.1016/j.cellsig.2012.10.004 [DOI] [PubMed] [Google Scholar]
  • 30.Neri P, Ren L, Gratton K, et al. Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors. Blood. 2011;118(24):6368–6379. doi: 10.1182/blood-2011-06-363911 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ito T, Handa H. Molecular mechanisms of thalidomide and its derivatives. Proc Jpn Acad Ser B. 2020;96(6):189–203. doi: 10.2183/pjab.96.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4(4):314–322. doi: 10.1038/nrc1323 [DOI] [PubMed] [Google Scholar]
  • 33.Slavin TP, Maxwell KN, Lilyquist J, et al. The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. NPJ Breast Cancer. 2017;3(1):22. doi: 10.1038/s41523-017-0024-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Levy-Lahad E, Lahad A, Eisenberg S, et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci. 2001;98(6):3232–3236. doi: 10.1073/pnas.051624098 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ross FM, Avet-Loiseau H, Ameye G, et al. Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012;97(8):1272–1277. doi: 10.3324/haematol.2011.056176 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Dmoszyńska A, Chocholska S. Molecular biology methods in the diagnosis of multiple myeloma. 2012:443–449. doi: 10.1007/978-3-642-29467-9_27 [DOI]
  • 37.Ahmann GJ, Jalal SM, Juneau AL, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet. 1998;101(1):7–11. doi: 10.1016/S0165-4608(97)00058-7 [DOI] [PubMed] [Google Scholar]
  • 38.Zmorzyński S, Popek-Marciniec S, Szudy-Szczyrek A, et al. The association of GSTT1, GSTM1, and TNF-α polymorphisms with the risk and outcome in multiple myeloma. Front Oncol. 2019;9. doi: 10.3389/fonc.2019.01056 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Lin B, Pang Z. Stability of methods for differential expression analysis of RNA-seq data. BMC Genomics. 2019;20(1):35. doi: 10.1186/s12864-018-5390-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Tarazona S, García-Alcalde F, Dopazo J, Ferrer A, Conesa A. Differential expression in RNA-seq: a matter of depth. Genome Res. 2011;21(12):2213–2223. doi: 10.1101/gr.124321.111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Bacchetti P, Leung JM. Sample size calculations in clinical research. Anesthesiology. 2002;97(4):1028–1029. doi: 10.1097/00000542-200210000-00050 [DOI] [PubMed] [Google Scholar]
  • 42.Aksenova AY, Zhuk AS, Lada AG, et al. Genome instability in multiple myeloma: facts and factors. Cancers. 2021;13(23):5949. doi: 10.3390/cancers13235949 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Neuse CJ, Lomas OC, Schliemann C, et al. Genome instability in multiple myeloma. Leukemia. 2020;34(11):2887–2897. doi: 10.1038/s41375-020-0921-y [DOI] [PubMed] [Google Scholar]
  • 44.Tambini CE, Spink KG, Ross CJ, Hill MA, Thacker J. The importance of XRCC2 in RAD51-related DNA damage repair. DNA Repair (Amst). 2010;9(5):517–525. doi: 10.1016/j.dnarep.2010.01.016 [DOI] [PubMed] [Google Scholar]
  • 45.Warsy A, Tulbah S, AbdulKareen H, et al. Polymorphisms in RAD51 and their relation with breast cancer in Saudi females. Onco Targets Ther. 2016:269. doi: 10.2147/OTT.S93343 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Ricks-Santi LJ, Sucheston LE, Yang Y, et al. Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk. BMC Cancer. 2011;11(1):278. doi: 10.1186/1471-2407-11-278 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Parvin S, Islam MDS, Al-Mamun MMDA, et al. Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population. Breast Cancer. 2017;24(2):229–237. doi: 10.1007/s12282-016-0692-5 [DOI] [PubMed] [Google Scholar]
  • 48.Al Zoubi MS, AL-Eitan LN, Rababa’h DM, et al. RAD51-UTR haplotype genetic polymorphisms and susceptibility to breast cancer in women from Jordanian population. Exp Oncol. 2023;43(2):149–154. doi: 10.32471/exp-oncology.2312-8852 [DOI] [PubMed] [Google Scholar]
  • 49.Gupta P, Sambyal V, Guleria K, Uppal MS, Sudan M. Association of RAD51, XRCC1, XRCC2, and XRCC3 polymorphisms with risk of breast cancer. Genet Test Mol Biomarkers. 2023;27(7):205–214. doi: 10.1089/gtmb.2023.0012 [DOI] [PubMed] [Google Scholar]
  • 50.Grešner P, Jabłońska E, Gromadzińska J. Rad51 paralogs and the risk of unselected breast cancer: a case-control study. PLoS One. 2020;15(1):e0226976. doi: 10.1371/journal.pone.0226976 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Mohseni A, Toogeh G, Rostami S, Faranoush M, Sharifi MJ. RAD51 and RAD50 genetic polymorphisms from homologous recombination repair pathway are associated with disease outcomes and organ toxicities in AML. Blood Res. 2024;59(1):46. doi: 10.1007/s44313-024-00033-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Mucha B, Przybyłowska-Sygut K, Dziki Ł, Dziki A, Sygut A, Majsterek I. Lack of association between the 135G/C Rad51 gene polymorphism and the risk of colorectal cancer among Polish population. Polish J Surg. 2012;84(7). doi: 10.2478/v10035-012-0060-x [DOI] [PubMed] [Google Scholar]
  • 53.Rollinson S, Smith AG, Allan JM, et al. RAD51 homologous recombination repair gene haplotypes and risk of acute myeloid leukaemia. Leuk Res. 2007;31(2):169–174. doi: 10.1016/j.leukres.2006.05.028 [DOI] [PubMed] [Google Scholar]
  • 54.Seedhouse C, Faulkner R, Ashraf N, Das-Gupta E, Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res. 2004;10(8):2675–2680. doi: 10.1158/1078-0432.CCR-03-0372 [DOI] [PubMed] [Google Scholar]
  • 55.Voso MT, Fabiani E, D’Alo’ F, et al. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Ann Oncol. 2007;18(9):1523–1528. doi: 10.1093/annonc/mdm191 [DOI] [PubMed] [Google Scholar]
  • 56.Li C, Liu Y, Hu Z, Zhou Y. Genetic polymorphisms of RAD51 and XRCC3 and acute myeloid leukemia risk: a meta-analysis. Leuk Lymphoma. 2014;55(6):1309–1319. doi: 10.3109/10428194.2013.835404 [DOI] [PubMed] [Google Scholar]
  • 57.Dastgheib SA, Sayad S, Azizi S, et al. Association between XRCC2 Arg188His polymorphism and breast cancer susceptibility: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2024;25(1):43–55. doi: 10.31557/APJCP.2024.25.1.43 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Xu D, Liang D, Guo Y, Sun Y. Endosulfan causes the alterations of DNA damage response through ATM-p53 signaling pathway in human leukemia cells. Environ Pollut. 2018;238:1048–1055. doi: 10.1016/j.envpol.2018.03.044 [DOI] [PubMed] [Google Scholar]
  • 59.Rajagopal T, Seshachalam A, Rathnam KK, Talluri S, Venkatabalasubramanian S, Dunna NR. Homologous recombination DNA repair gene RAD51, XRCC2 & XRCC3 polymorphisms and breast cancer risk in South Indian women. PLoS One. 2022;17(1):e0259761. doi: 10.1371/journal.pone.0259761 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Saeed S, Mahjabeen I, Sarwar R, Bashir K, Kayani MA. Haplotype analysis of XRCC2 gene polymorphisms and association with increased risk of head and neck cancer. Sci Rep. 2017;7(1):13210. doi: 10.1038/s41598-017-13461-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Wang Z, Wei Y, An L, et al. XRCC2 Arg188His polymorphism and colorectal cancer risk: a meta-analysis. J Int Med Res. 2021;49(10). doi: 10.1177/03000605211039473 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Fehrmann RSN, Jansen RC, Veldink JH, et al. Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. PLoS Genet. 2011;7(8):e1002197. doi: 10.1371/journal.pgen.1002197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Lutz S, Brion C, Kliebhan M, Albert FW. DNA variants affecting the expression of numerous genes in trans have diverse mechanisms of action and evolutionary histories. PLoS Genet. 2019;15(11):e1008375. doi: 10.1371/journal.pgen.1008375 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Howard SM, Yanez DA, Stark JM. DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining. PLoS Genet. 2015;11(1):e1004943. doi: 10.1371/journal.pgen.1004943 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res. 2007;67(15):7395–7405. doi: 10.1158/0008-5472.CAN-07-1015 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The clinical data used to support the findings of this study are available from the corresponding author upon request.


Articles from The Application of Clinical Genetics are provided here courtesy of Dove Press

RESOURCES